ADDvise acquires Medisuite, LLC

30-07-2021   Regulatory press release

ADDvise Group AB has today entered into a share purchase agreement with the owner of Medisuite LLC regarding the acquisition of all the outstanding shares of Medisuite, LLC in accordance with the letter of intent communicated via a press release dated 24th May 2021. Closing of the acquisition is expected to take place in August 2021.

Medisuite is an American online pharmacy, based in Cary, North Carolina, that specializes in medication for men’s health. The company holds licenses to distribute pharmaceuticals in all but two states in the U.S. The assessment is that the company, after the acquisition, will acquire licenses for the two missing states also. The licenses are not tied to specific pharmaceuticals. Medisuite’s revenue for the year 2020 amounted to approximately USD 3.04 million, with an adjusted EBITDA of approximately USD 1.45 million, an EBITDA-margin of roughly 48%.

As previously communicated, the purchase price amounts to a total of approximately USD 10.30 million, divided into an initial payment of approximately USD 6.50 million on a cash and debt-free basis, an interest-free non-recourse promissory note of USD 1.30 million and two potential earn-outs, given that the seller achieves certain predetermined targets. The potential earn-outs amount to maximum of USD 1.0 million for the fiscal year 2022 and USD 1.5 million for the fiscal year 2023.

The acquisition is financed through own funds. ADDvise assesses that the acquisition will have a positive impact on ADDvise earnings per share during the financial year 2021.

Advisor

Mangold Fondkommission AB is the financial advisor to ADDvise for the acquisition.

For further information, please contact:

Rikard Akhtarzand, CEO

+46 765-25 90 71

rikard.akhtarzand@addvisegroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.se.      

Latest press releases

Notice to the annual general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 12 May 2025 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the…

ADDvise raises approximately SEK 457 million in the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…

ADDvise Group publishes annual report and sustainability report for 2024

Regulatory

Today, ADDvise Group AB (publ) is publishing the annual report and the sustainability report for 2024. Both reports are available on ADDvise’s website: www.addvisegroup.com. The annual report and the sustainability report are published in Swedish and English. The Swedish versions represent the originals. For further information, please contact: Staffan Torstensson, CEO +46 (0)70-433 20 19…

ADDvise announces preliminary outcome of the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…